BioNTech (NASDAQ:BNTX) Receives "Buy" Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of BioNTech (NASDAQ:BNTX - Free Report) in a research report sent to investors on Wednesday morning,Benzinga reports. They currently have a $138.00 price objective on the stock. HC Wainwright also issued estimates for BioNTech's Q2 2025 earnings at $3.78 EPS.

BNTX has been the topic of a number of other reports. Truist Financial restated a "buy" rating and issued a $155.00 price objective (up from $151.00) on shares of BioNTech in a research note on Tuesday, June 3rd. Leerink Partners set a $112.00 price target on BioNTech in a research report on Monday, June 2nd. The Goldman Sachs Group began coverage on BioNTech in a research note on Thursday, May 29th. They set a "neutral" rating and a $110.00 price objective for the company. Canaccord Genuity Group reiterated a "buy" rating and issued a $171.44 target price on shares of BioNTech in a research note on Tuesday, March 11th. Finally, Citigroup reissued a "buy" rating and issued a $140.00 target price (down previously from $145.00) on shares of BioNTech in a report on Tuesday, May 6th. Five research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $137.86.

BioNTech Stock Up 1.3%

BNTX traded up $1.34 during trading on Wednesday, hitting $106.14. 402,644 shares of the stock were exchanged, compared to its average volume of 943,899. The company has a current ratio of 10.18, a quick ratio of 10.02 and a debt-to-equity ratio of 0.01. BioNTech has a 1-year low of $76.53 and a 1-year high of $131.49. The stock has a fifty day moving average price of $102.49 and a two-hundred day moving average price of $107.40.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Banque Cantonale Vaudoise acquired a new stake in shares of BioNTech in the 1st quarter worth approximately $36,000. Jones Financial Companies Lllp boosted its position in BioNTech by 110.3% during the fourth quarter. Jones Financial Companies Lllp now owns 469 shares of the company's stock worth $53,000 after purchasing an additional 246 shares in the last quarter. Quintet Private Bank Europe S.A. grew its holdings in BioNTech by 823.5% in the fourth quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company's stock valued at $88,000 after purchasing an additional 700 shares during the last quarter. Allianz SE purchased a new position in shares of BioNTech in the fourth quarter valued at $90,000. Finally, Banque Transatlantique SA purchased a new position in shares of BioNTech in the first quarter valued at $80,000. 15.52% of the stock is owned by hedge funds and other institutional investors.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.